Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
3420090 | Revue de Pneumologie Clinique | 2008 | 4 Pages |
Abstract
Erythopoietin (EPO) treatment of anemia during cancer has dramatically improved the tolerance of chemotherapy and quality of life of patients at all stages of the disease. Several surveys have demonstrated a high prevalence and a high incidence of anemia in lung cancer patients. The guidelines updates concerning EPO treatment for these patients are described. They take into account the debate concerning the potential harm of these molecules on the neoplastic disease and the possible role of EPO receptors expressed by several tumors, including non small cell lung cancer.
Related Topics
Health Sciences
Medicine and Dentistry
Infectious Diseases
Authors
J.-M. Bréchot, J.-F. Morère,